Compare LSPD & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSPD | KLRA |
|---|---|---|
| Founded | 2005 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2020 | 2026 |
| Metric | LSPD | KLRA |
|---|---|---|
| Price | $9.79 | $10.88 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $13.33 | N/A |
| AVG Volume (30 Days) | 549.6K | ★ 976.4K |
| Earning Date | 05-21-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.43 | N/A |
| Revenue Next Year | $10.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.83 | $10.83 |
| 52 Week High | $13.72 | $23.82 |
| Indicator | LSPD | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 27.45 |
| Support Level | $9.34 | N/A |
| Resistance Level | $9.83 | $19.15 |
| Average True Range (ATR) | 0.24 | 0.86 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 30.05 | 1.53 |
Lightspeed Commerce Inc is a one-stop commerce platform providing its customers with the critical functionalities needed to engage with consumers, manage their operations, order their inventory, accept payments, and run their business. It has customers globally in over 100 countries, empowering single- and multi-location small and medium-sized businesses to compete in an omni-channel market environment by engaging with consumers across online, mobile, social, and physical channels. Its products are divided into retail, restaurant, and golf categories. Geographically, it operates in Canada, the United States, the United Kingdom, Switzerland, Germany, and Others with the majority of revenue deriving from Canada.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.